What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?

Current Controlled Trials in Cardiovascular Medicine

Volumn 1, Issue 3, 2000, Pages 166-171

  Kobashigawa, J ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Cardiac allograft vasculopathy; Heart transplantation; prophylaxis

Indexed keywords

ANGIOPEPTIN; ANTILIPEMIC AGENT; ANTITHROMBIN III CONCENTRATE; B LYMPHOCYTE ANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; CYTOKINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIRULOG; HLA ANTIBODY; HLA ANTIGEN; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; LEUKOTRIENE DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ALLOTRANSPLANTATION; CARDIOVASCULAR RISK; CELL DAMAGE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INCIDENCE; MORTALITY; PATHOGENESIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; RECIPIENT; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0034466751     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-1-3-166     Document Type: Review

References (35)

1. Histopathology of graft coronary disease
2. Cardiac allograft vasculopathy: The central pathogenetic role of ischemia-induced endothelial cell injury
3. Transplant coronary disease: Non-immunologic risk factors
4. Post-transplant obesity and hyperlipidemia: Major predictors of severity of coronary arteriopathy in failed human heart allografts
5. Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound
6. Immune and nonimmune mechanisms of chronic rejection of kidney allografts
7. Quantitative analysis of transplant coronary artery disease with use of intracoronary ultrasound
8. Does intracoronary ultrasound conflict with pathology? Comments from a panel discussion
9. The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: A paradigm shift
10. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation
11. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease
12. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients
13. Prevention of transplant accelerated coronary vascular disease with diltiazem [abstract]
14. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy
15. Diltiazem modulates monokine production in human mixed lymphocyte culture
16. Amlodipine reduces graft coronary artery disease in rat heterotopic allografts
17. Calcium antagonists and atherosclerosis
18. Effect of pravastatin on outcomes after cardiac transplantation
19. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
20. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A 4-year randomized trial
21. Stimulation of p21ras upon T-cell activation
22. Inhibition of transplant vasculopathy by pravastatin is associated with attenuated host allo-antibody response
23. Humoral immune responses after cardiac transplantation: Correlation with fatal rejection and graft atherosclerosis
24. Anti-donor HLA antibodies associated with allograft arteriopathy detected using intravascular ultrasound
25. Effects of pravastatin on chronic rejection of rat cardiac allografts
26. Angiopeptin: A treatment for accelerated myointimal hyperplasia?
27. Preventive treatment of coronary vasculopathy in heart transplantation by inhibition of smooth muscle cell proliferation with angiopeptin
28. Photochemotherapy for the prevention of graft atherosclerosis in cardiac transplantation [abstract]
29. Effect of mycophenolate mofetil on allograft arteriosclerosis
30. Effects of cyclosporine and 15-deozyspergualin on coronary arteriosclerosis after heart transplantation in the rat
31. Effects of cyclosporine, FK506, and rapamycin on graft vessel disease
32. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine
33. Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: From bench to bedside
34. Captopril reduces graft coronary artery disease in rat heterotopic transplant model
35. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: A comparative study with captopril